Date: December 15-17, 2021 Venue: Moscone Center, San Francisco, California NCIA’s 7th Annual Cannabis Business Summit & Expo will be held in the Moscone Center in San Francisco, California, on December 15-17, 2021. Hosted by the National Cannabis Industry Association (“NCIA”), the largest and oldest national trade association advancing the interests of the legal cannabis industry, the three-day event showcases cannabis industry professionals and advocates Troy Datcher, Calvin Johnson, Jr., Rachael Rapinoe, Anna Symonds, and Marvin Washington as keynote speakers. Key Points:

• Leading a new generation of c-suite innovators, Chief Executive Officer Troy Datcher, together with Chief Visionary Officer Shawn “JAY-Z” Carter, helms a cannabis business for the post-prohibition era at The Parent Company. Combining best-in-class operations with leading voices in popular culture and social impact, The Parent Company focuses on building brands that will pave a new path forward for a legacy rooted in equity, access, and justice.
• Troy Datcher will share his personal story and enlighten guests on his endeavor to create an impact in the cannabis industry in a “fireside chat” with MARY Magazine founder, Adrian Farquharson, at 10AM on Thursday, December 16.
• The second keynote, entitled ‘Wellness in Action: Elite Athletes as Cannabis Advocates,’ moderated by entrepreneur Jim McAlpine, will feature professional athletes and cannabis advocates Calvin Johnson, Jr., Rachael Rapinoe, Anna Symonds, and Marvin Washington of Athletes for CARE.
• This panel will discuss a variety of issues, including the progression and acceptance of cannabis in sports, as well as how athletes may have a significant impact on cannabis policy, at 10AM on Friday, December 17.

Why is #CannaBizSummit a Can’t-Miss Event? NCIA’s 7th Annual Cannabis Business Summit & Expo is the industry’s most significant national B2B trade exhibition, and the only event that brings together an exclusive lineup of education, exhibitors, and experiences under one roof. Over 125 speakers, more than 80 educational sessions, and hundreds of exhibitors will be featured at #CannaBizSummit 2021. Furthermore, at mixers and happy hours, event guests from throughout the country, including licensed retailers, cultivators, manufacturers, and consumer enthusiasts, will have the opportunity to make meaningful connections with fellow cannabis industry professionals. In addition, this year’s #CannaBizSummit venue was chosen for its historical relevance in the cannabis industry. San Francisco is both the gateway to the Emerald Triangle, the country’s largest cannabis-producing region, and the epicenter of the reform movement. For more information, please visit https://ibn.fm/ZUMXO

• PlantX is celebrating the expansion of its e-commerce platform to the United Kingdom
• The platform will offer a wide array of plant-based products, indoor plants, and educational resources
• The UK is the leading market for plant-based alternatives in Europe and has in the recent past witnessed changes that align perfectly with PlantX’s recent move
• The launch of the site fulfills the company’s mission and is a step in the right direction for the PlantX

In line with its mission of bringing more plant-based options to as many people as possible, PlantX Life (CSE: VEGA) (Frankfurt: WNT1) (OTCQB: PLTXF) has announced the expansion of its e-commerce platform to the United Kingdom (“UK”). Set to be launched under the domain www.PlantX.uk, the new platform will offer customers a similar experience as PlantX’s customers in Canada and the United States have become accustomed to (https://ibn.fm/o5a3e). In addition to complementing Bloomboxclub UK, PlantX’s UK-based subsidiary that sells and delivers indoor plants across the United Kingdom and Germany via an online shop and subscription service, the new UK site will feature a wide array of plant-based goods, an assortment of educational resources such as blogs and recipes, and an extensive selection of indoor plants. “PlantX plans to introduce a wide selection of novel brands and products for the growing plant-based community in the United Kingdom,” commented company COO Julia Frank. “By offering consumers access to products that are new to the UK market, PlantX hopes to secure a competitive advantage in the dynamic plant-based retail ecosystem in the UK throughout and beyond the upcoming holiday season.” The timely launch dovetails with emerging trends in the UK’s plant-based space. According to a study conducted by the London School of Hygiene & Tropical Medicine (“LSHTM”) in collaboration with the University of Oxford, the proportion of UK people who reported eating and eating plant-based alternative foods nearly doubled between 2008-2011 and 2017-2019 from 6.7% to 13.1% (https://ibn.fm/Hq7Na). “The researchers say their study suggests that alternative plant-based foods are likely to play an important role in dietary change away from meat and dairy, and take a considerable place in UK diets,” reads a summary of the report. The LSHTM study is consistent with findings from separate research from the University of Oxford. According to this research, the daily meat consumption in the UK decreased by 17% between 2008/2009 and 2018/2019 (https://ibn.fm/MUP5g). Relatedly, a Mintel Research report established that the proportion of people who have limited or reduced their meat consumption increased from 28% in 2017 to 39% in 2019. Put together, these statistics have contributed to the UK’s status as the largest market for plant-based alternatives in Europe. Here, sales of meat-free foods increased by 40% from £582 million (US$771 million) in 2014 to an estimated £816 million (US$1.081 billion) in 2019. Mintel projects that this figure will grow further to more than £1.1 billion (US$1.458 billion) by 2024 (https://ibn.fm/NUkm4). In this regard, the new e-commerce site enables PlantX to tap into the UK’s appetite for plant-based alternatives and, through educational resources, possibly enhance the population’s knowledge of plant-based products even further. On his part, PlantX Founder, Sean Dollinger, noted that accessing the vast and flourishing UK market is a critical part of the company’s business plan, further underscoring that PlantX sees the launch as another step in the right direction. “Introducing new plant-based options to additional growing market segments is a recipe for success,” said PlantX CEO Lorne Rapkin. “Having our e-commerce site operational in the UK is the next evolutionary step on our way to expanding across the globe, and we’re excited to serve this market segment.” Notably, PlantX has partnered with one of the leading fulfillment companies in the UK, Access Fulfillment, to establish an effective supply chain infrastructure. With more than 20,000 square feet of warehouse space complete with refrigeration capabilities, Access’s facilities will ensure the centralized storage and distribution of PlantX’s plant-based products across the UK. For more information, visit the company’s websites at www.PlantX.com, www.PlantX.ca, and https://investor.plantx.com/ and view PlantX for Plant-Based Investors. NOTE TO INVESTORS: The latest news and updates relating to PLTXF are available in the company’s newsroom at https://ibn.fm/PLTXF

• MINDCURE President and CEO Kelsey Ramsden will participate in, and has already attended multiple industry conferences throughout December
• Participation in #CanndoraConnect: Women in Psychedelics Conference focused on exploring job opportunities in psychedelics
• Company remains focused on promoting healing and improving mental health via digital therapeutics technology and psychedelic compounds research
• Company reports that 971 million people worldwide suffer from a mental disorder. As of 2019, MINDCURE calculates that 12,472 registered mental health facilities treatment facilities could benefit from the company’s proprietary digital therapeutics technology, iSTRYM
• The global digital therapeutics market is valued at $3.4 billion and is projected to reach $13.1 billion by 2026, primarily driven by the growing need for control over healthcare costs and the rising focus on preventative health opportunities

Life sciences company Mind Cure Health (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH) a leader in advanced proprietary technology and research for psychedelics, is rounding out 2021 by participating in the Life Sciences Investor Forum, a virtual investor conference that provides a fully interactive forum where publicly-traded companies can meet and present directly to investors. President and CEO of MINDCURE, Kelsey Ramsden, will be presenting virtually during the Life Sciences Investor Forum – which will be available archived on the conference’s website after the event has concluded (https://ibn.fm/q34CM). The virtual forum will take place on December 16, 2021, with MINDCURE presenting at 11:30 AM EST. Ms. Ramsden has already presented at three other industry events thus far in December – including the H.C. Wainwright 2nd Annual Psychedelics Conference on December 6, the Psychedelics Now Virtual Conference on December 8, and #CanndoraConnect: Women in Psychedelics Conference on December 8. The presentation at H.C. Wainwright will be available to the public for 90 days following the conference, on MINDCURE’s investor relations website, and requires registration (https://ibn.fm/dzpnW). At the Psychedelics Now Virtual Conference, Ms. Ramsden participated in the “Road to Monetization” webcast panel, which is currently available online (https://ibn.fm/WEZe4). Registration is required to view the panel. Ms. Ramsden’s participation in #CanndoraConnect: Women in Psychedelics Conference focused on exploring job opportunities in psychedelics. MINDCURE expects growing job opportunities in the industry, as the psychedelics sector is expanding. Research cited by the company indicates that the global functional mushroom market will reach a value of $37 billion by 2025, up from the $23 billion value it held in 2019 (https://ibn.fm/Cx5M8). The company’s focus on developing psychedelic compounds to scale science-backed and evidentiary-based mental health therapy worldwide via digital therapeutics were among the topics discussed at December’s events. Part of MINDCURE’s philosophy is about investing in the moment, and MINDCURE’s moment focuses on the psychedelic and digital therapeutics markets. The company reports that 971 million people worldwide suffer from a mental disorder. As of 2019, MINDCURE calculates that 12,472 registered mental health treatment facilities could benefit from the company’s proprietary digital therapeutics technology, iSTRYM. The minimum viable product version of iSTRYM was so far made available to 20 ketamine clinics in nine different states in the U.S. and three Canadian provinces, and the company plans to launch full commercial deployment in Q1 or Q2 next year and to enter the European market later in 2022. As member of the Digital Therapeutics Alliance with a dedicated product that is already being used successfully, MINDCURE has a prominent position in the global digital therapeutics market. This market is currently valued at $3.4 billion, according to 2021 figures. The market is projected to reach $13.1 billion by 2026, growing at a CAGR of 31.4%. This growth is being facilitated by the need to control healthcare costs and the rising focus on preventative healthcare options (https://ibn.fm/mE4wv). For more information, visit the company’s website at www.MindCure.com. NOTE TO INVESTORS: The latest news and updates relating to MCURF are available in the company’s newsroom at http://ibn.fm/MCURF

• Lexaria Bioscience plans to launch approximately 12 applied research and development programs in 2022
• The programs are designed to explore the ability of the company’s patented DehydraTECH(TM) to improve drug delivery processes for multiple indications
• Research will continue into the use of DehydraTECH-CBD for high blood pressure, as well as the technology’s potential for oral nicotine delivery

Diabetes, rheumatoid disease, Alzheimer’s Disease, and estrogen delivery, are some of the multiple indications that drug delivery platform innovator Lexaria Bioscience (NASDAQ: LEXX) is planning to target with its research and development programs next year. The markets targeted provide multiple opportunities for success and are now expected to reach an overall estimated value of more than $160 billion annually, worldwide over the next few years. The company will conduct pharmacokinetic and efficacy modelling studies to determine if its patented DehydraTECH(TM) technology can be used successfully to improve delivery of drugs or active pharmaceutical ingredients in these sectors, and to determine if there are specific commercial benefits to continue pursuing these markets. The largest sector targeted by the company is currently the diabetes therapeutics market, expected to reach $77.9 billion worldwide by 2024 (https://ibn.fm/PAFA0). With diabetes being the seventh largest cause of death in the United States, the market has the potential to generate impressive growth opportunities for the company. Lexaria’s R&D program for this indication, titled DIAB-A22-1 and likely to be launched in November 2022, will explore the impact of cannabidiol (“CBD”) delivered through the company’s proprietary DehydraTECH technology. Another major target market the company is the rheumatoid arthritis therapeutics sector, expected to reach a value of over $30 billion per year by 2025 (https://ibn.fm/pYzqd). There are currently over 100 rheumatic diseases, including rheumatoid arthritis, osteoarthritis, and fibromyalgia. The company’s RHEUM-A22-1 efficacy study, likely to be launched in October 2022, will look into how DehydraTECH-CBD can potentially affect the treatment of rheumatoid arthritis, given CBD’s efficacy to reduce inflammation. The program DEM-A22-1, likely to begin in July 2022, will assess the use of DehydraTECH-delivered CBD, both paired with nicotine and without it, for the potential treatment of dementia. The dementia therapeutics market is estimated to reach $19.6 billion by 2026 and there are currently about 55 million people affected by dementia worldwide, with approximately 78 million more expected to face some form of dementia by 2030 (https://ibn.fm/aQpsi). The most common form of dementia is Alzheimer’s disease, accounting for roughly 60 percent of all cases. Another program targeting a major market is HOR-A22-1, a pharmacokinetic study that will try to determine if DehydraTECH can be used to enhance and improve the delivery characteristics of estrogen. Amid growing awareness of post-menopausal issues women face, and an increase in the prevalence of menopausal disorder, the hormone replacement market is anticipated to grow exponentially and reach $46.5 billion by 2027 (https://ibn.fm/8trBY). Lexaria Bioscience’s estrogen delivery study is tentatively scheduled to being in April 2022. In addition to the new R&D programs, Lexaria will continue the programs launched previously to explore the potential impact of DehydraTECH-delivered CBD on hypertension and heart disease, as well as the technology’s use for oral nicotine delivery as a potential alternative to smoking. Heart disease and smoking are the first and third, respectively, causes of death in the United States. With all the programs for 2022 fully funded due to the $15 million raised by the company this year, Lexaria is going into the new year with a busy roster of R&D programs. For more information, visit the company’s website at www.LexariaBioscience.com. NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

• Applied Magix is currently shipping five products to customers
• The company plans to add new products to its offerings in 2022
• Applied Magix is positioned to take advantage of unmet demand for Apple-compatible smart home and connected car products
• The global smart home market is forecast to hit more than $187 billion in revenue by 2025, marking a CAGR of 15.75 percent from 2021
• The company operates in rapidly growing markets
• Both SPYR and its Applied MagiX subsidiary have experienced management teams in place

SPYR (OTCQB: SPYR), dba SPYR Technologies, is a technology company which, through its Applied MagiX Inc. subsidiary, develops and resells Apple(R)-ecosystem-compatible products with an emphasis on the growing, multibillion-dollar Internet of Things (“IoT”) Smart Home and Connected Car markets. SPYR continues to identify and target acquisitions with an aim of growing its footprint in the industry and expanding the products it offers consumers, including companies developing artificial intelligence and smart-technology products. In 2020, SPYR acquired Applied MagiX Inc., a registered Apple developer and reseller of Apple ecosystem compatible products with an emphasis on the smart home market, as a wholly owned subsidiary. Applied MagiX operates in the IoT market and, more specifically, the segment of the market related to the development, manufacture and sale of devices and accessories specifically built on Apple’s HomeKit(R) framework. These products work within the Apple HomeKit ecosystem and are exclusive to the Apple market and its consumers. Initially, while working to develop, manufacture and sell its own line of branded products, Applied MagiX will be sourcing HomeKit products and accessories from worldwide manufacturers, vetting and selecting best-of-breed products, selling them directly to consumers and supporting them. The company focuses on Apple consumers – a target market with higher disposable income and a demonstrated willingness to pay a premium for quality products. On average, Apple product users spend roughly twice as much on technology as other smartphone users. Those who purchase smart home products spend more than $3,000 on average. By creating smart hardware and software solutions exclusively for Apple consumers, SPYR addresses a problem faced by that market – having few “smart” devices that integrate with Apple’s HomeKit, despite being the most affluent and loyal consumers of tech products. Products The company’s Applied MagiX subsidiary offers multiple product lines to its target markets. First, the subsidiary is a reseller of third-party manufactured Apple HomeKit and Apple CarPlay compatible products. HomeKit comes pre-installed on every new iPhone, while the CarPlay platform is licensed by all major auto manufacturers. Applied MagiX identifies white label products, applies the company’s branding, improves the software and sells these improved products to consumers. Finally, Applied MagiX is developing its own proprietary line of smart home and connected car products, including Apple-compatible home cameras, sensors and alarms, as well as additional Apple-compatible smart car products in the iOS ecosystem. Among the subsidiary’s products sold to consumers are:

• The MagixDrive Wireless CarPlay adapter, which allows users to access CarPlay wirelessly using their iPhones
• The HomeKit Secure Video Camera with iCloud Storage
• The Multipurpose Sensor with Alarm
• The Environment and Motion Sensor
• The Window and Door Contact Sensor

Market Outlook According to Statista, the global smart home market is expected to generate revenue of more than $104 billion in 2021. The market is forecast to hit more than $187 billion in revenue by 2025, recording a CAGR of 15.75 percent. The number of active households in the worldwide smart home market is expected to reach nearly 500 million by 2025. Household penetration is just over 12 percent in 2021 and is projected to nearly double by 2025 to more than 22 percent. Allied Market Research valued the global connected car market at more than $63 billion in 2019 and projected a CAGR of 17.1 percent, which would push revenue to more than $225 billion by 2027. Allied identified rising consumer demand for connectivity solutions, surging need for constant connectivity, increasing dependency on technology and an upsurge in tech-savvy population as key factors driving the projected growth of the connected car market. Management Team James R. Thompson is the CEO, President and General Counsel of SPYR. Over the past 28 years, Mr. Thompson has deftly managed a colorful spectrum of legal clients and situations. In the process, he has helped many companies – both large and small – thrive. Now he welcomes the challenge to take the company and his career in an entirely new direction. A native of Philadelphia, he holds a J.D. from Rutgers University and a Bachelor of Science from the University of Denver. Jennifer Duettra is the Executive Vice President of SPYR. She brings a great deal of knowledge in mobile gaming and pop culture to the company. She is an attorney and was thrilled by the prospect to combine her law experience with a chance to be creative. She is a native of Colorado and received her Bachelor of Arts in Political Science and Speech Communication from Colorado State University. She holds a J.D. from Harvard University. Trang Nguyen is the CFO of SPYR. From 2019 to 2020, she served as the Financial Reporting Manager for Del Taco, where she was responsible for the preparation and filing of periodic financial reports with the U.S. Securities and Exchange Commission. From 2016 through 2019, Ms. Nguyen was Accounting Manager for Pinnacle Tax Accounting in Los Angeles, California. She was a part of Ernst & Young’s audit team in Los Angeles from 2006 to 2008, leading engagements on interim and year-end ad SOX 404 auditing procedures for major enterprise accounts. Ms. Nguyen holds a Bachelor of Art, Business Economics (Minor in Accounting) from the University of California, Los Angeles. She is a certified public accountant with an inactive license. Dr. Harald Zink is the CEO, Founder and Chief Product Architect of SPYR subsidiary Applied MagiX. Prior to founding Applied MagiX, he was Director of Technologies and later Vice President of Technologies at Sarkissian Productions in Los Angeles. He also served as Director of Technologies at SMZ Technologies and, for more than 17 years, as Macintosh Technology Consultant to The Walt Disney Studios in Burbank, California. He speaks five languages and holds degrees from the University of California, Riverside. Kelly Clark is the COO of Applied MagiX. Before joining the subsidiary, he worked as Vice President of Sales Operations at TruClear Global. Prior to that, Mr. Clark was Senior Director of Program Management at Pacific Group Ventures and Operations Manager at Barco. He has also held operations management positions at Deluxe Digital Studios and Sony Pictures Entertainment. Mr. Clark holds a bachelor’s degree in international business from the University of Southern California. For more information, visit the company’s website at www.Spyr.com. NOTE TO INVESTORS: The latest news and updates relating to SPYR are available in the company’s newsroom at https://ibn.fm/SPYR

• The full patent application covers multiple families of psilocin analogs. Psilocin is the active metabolite of psilocybin
• In addition to improving delivery control, the company’s dermal application route can potentially eliminate undesirable side effects such as nausea
• Mydecine appoints Dr. Saeid Babaei, PhD, as an independent board member. The appointment can help advance the company’s NASDAQ listing efforts, bringing decades of experience in biotech development and licensing and strategic advancements
• Company intends to uplist to NASDAQ in Q1 2022

Improving delivery control and shelf stabilization of psilocybin’s active metabolite psilocin, two critical aspects for use in medical settings, is the key goal of a new patent application filed by Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA), a biotech and digital technology company focused on transforming the treatment of mental health and addiction disorders. The full patent application Mydecine filed covers multiple families of psilocin analogs, according to a company press release. “The goal of creating these improved second-generation compounds is to enable safer, more effective treatments for patients along with improved management of dosage and drug behavior for clinicians,” Mydecine Chief Science Officer Rob Roscow said, talking about the patent application in the context of the company’s R&D pipeline of nature-sourced psychedelic-assisted therapeutics, therapy protocols, novel compounds and unique delivery systems. “We believe these improvements are necessary for psychedelic medicines to become an accepted and adopted form of treatment,” Roscow added. Mydecine’s patent offers solutions that primarily address controllability of delivery and stability, in view of increasing psilocin’s potential for medical use. More specifically, Mydecine’s dermal route for administration of psilocin can address controllability concerns resulting from variations in onset time for each patient when psilocybin is administered orally. The company’s permeation enhanced prodrug provides more control over delivery and can potentially eliminate side effects like nausea by bypassing the digestive system. The company’s patent filing also includes a family of stabilized psilocin analogs to optimize shelf stability, bringing Mydecine closer to a drug that meets regulatory requirements and providing access to a reliable and stable source of psilocin for physicians. This is the latest application in a series of patent filings for the company’s technology, as part of a sustained effort to build up and strengthen its intellectual property portfolio in its commitment to reimagine addiction and mental health treatment with more effective and safer solutions. In November 2021, Mydecine filed a technology patent covering the creation of formulations that use nanoemulsion technology to increase, improve and stabilize bioavailability of repeatable properties of ingredients from traditional medicine. And in September 2021, Mydecine filed a final patent application for one of its lead drug candidates, MYCO-003, a psilocybin formulation designed to enhance treatment of anxiety and post-traumatic stress disorder. To further advance its drug pipeline and compliance with NASDAQ requirements, the company appointed Dr. Saeid Babaei, PhD, as an independent board member to its board of directors. “We are pleased to welcome Dr. Babaei to the team as he brings decades of experience in biotechnology development, award-winning discoveries in gene therapy, and licensing and strategic advancements for the companies he has founded and accelerated,” Mydecine Chairman and CEO Josh Bartch said. Dr. Babaei has over 20 years of academic and corporate experience in bringing drug products from early development to commercialization. Dr. Babaei’s experience covers multiple novel and first-in-class products, as well as remarkable business foresight as he has closed more than 25 licensing and strategic alliance transactions and raised more than $50 million in equity and debt financing throughout his career. “As Mydecine continues to move our lead candidates down the pipeline, Dr. Babaei will play an integral role in advancing our novel psychedelic-based therapeutic candidates as well as meeting NASDAQ listing requirements,” Bartch added. Mydecine plans to uplist to NASDAQ in the first quarter of 2022. For more information, visit the company’s website at www.Mydecine.com. NOTE TO INVESTORS: The latest news and updates relating to MYCOF are available in the company’s newsroom at https://ibn.fm/MYCOF

• Rich communication services (“RCS”) provider and big data analysis solutions developer FingerMotion has announced an agreement with Munich Re to form a collaborative research alliance to benefit life and health insurance risk evaluation
• FingerMotion focuses its SMS, MMS, and big data products on China’s huge high-end phone consumer market
• The company’s most recent quarterly report noted a 25 percent YOY quarterly growth in revenues attributed to SMS and MMS services
• The Munich Re agreement follows FingerMotion’s contract earlier this year with Pacific Life Reinsurance to provide big data analytical services for Pacific Life’s insurance operations in China

Communications and big data technology platform builder FingerMotion (OTCQX: FNGR) is continuing to build reinsurance industry opportunities for its Sapientus data analysis platform, announcing Dec. 6 that its 99 percent-owned subsidiary Shanghai JiuGe Information Technology Co., Ltd. inked a collaborative research alliance with global reinsurance powerhouse Munich Re to improve understanding of morbidity and behavioral patterns in China’s marketplace, focusing on life and health insurance. “Today’s news sets the stage for a longer-term strategic mission to reinvent the way we provide insurance to customers in the future and transform the overall industry,” FingerMotion CEO Martin Shen stated (https://ibn.fm/8QoGF). “All the vital elements are in place,” Shen added. “With our distribution platform that enables wide-scale marketing throughout China, a growing network of partners and ongoing accumulation of increasing data points and observations will further strengthen our analytic power and extend our reach, enabling us to aid in the industry’s effort to better stratify risks and contain moral hazard, ultimately augmenting the efficiency of the overall insurance system.” FingerMotion is a U.S.-based mobile tech services provider that is focused on China’s consumer phone market, building revenues primarily from short and multimedia messaging (SMS and MMS) services there. But the company’s Sapientus division has caught the attention of insurance industry players, most notably global insurer Pacific Life. Pacific Life’s Re-insurance division in China finalized an agreement with FingerMotion earlier this year to receive consumer risk data generated by FingerMotion for efficiently processing claims while screening for fraud and abuse. China’s insurance risk and credit risk evaluation infrastructure is still underdeveloped, creating a particular need in the country for solutions such as the information Sapientus offers to help companies analyze consumer behaviors and establish predictive algorithms. “This is the third consecutive quarter of Big Data revenues and we expect it to continue and eventually outpace our existing revenue streams,” Shen stated earlier this fall (https://ibn.fm/RwHGj). The quarterly financial report released in conjunction with Shen’s statement noted 25 percent year-over-year growth in revenues attributed to SMS and MMS services, and an overall quarterly revenue growth to $5.39 million. For more information, visit the company’s website at www.FingerMotion.com. NOTE TO INVESTORS: The latest news and updates relating to FNGR are available in the company’s newsroom at https://ibn.fm/FNGR

• Colombian cannabis cultivator and international wellness product builder Flora Growth Corp. is building a global pipeline for its wide array of branded CBD and medicinal cannabis products
• The company recently announced that it has begun fulfilling the first orders for its Mind Naturals and Awe CBD skincare brands with exports to Spain and Mexico outlets this month
• Flora Growth cultivates cannabis at its 100-hectare (247-acre) property in central Colombia
• Flora also has a GMP certified 16,000-square-foot manufacturing facility in Bogota that produces nearly 200 products for the CBD derivatives and medical cannabis markets

Cannabis cultivator and worldwide cannabidiol (“CBD”) brand builder Flora Growth (NASDAQ: FLGC) continues to expand its consumer product goods and wellness lifestyle technology internationally, recently receiving its first orders for its Mind Naturals and Awe CBD skincare brands from outlets in Spain and Mexico. The company’s e-commerce agreements with SHOWFIELDS and GlossWire’s digital beauty marketplace in October paved the way for the two skincare brands to roll out in international markets. Fulfillment of these initial purchase orders from Amma Spain and Mexico’s Evergreen CBD is anticipated as the company’s product is exported this month. Mind Naturals markets to young, incoming consumers while Awe provides a customizable experience to the prestige market. “After months of preparation, our products meet all the needs of today’s consumers and we are ready for new international markets,” Flora Beauty General Manager Andrew Restrepo stated in announcing the product orders (https://ibn.fm/IfPIP). “Incorporating cutting edge formulations, rigorous safety standards and sustainable packaging, we are confident that our products are positioned to be among the best in the beauty industry and pleased that recent industry recognition supports this.” The announcement states Mind Naturals has garnered praise from industry marketing firms and that Spain is gaining a CBD hub reputation as a country poised to serve as the exporter for the industry’s products to surrounding countries. Flora Growth’s Flora Lab division serves as the company’s base for research, development and manufacturing of pharmaceuticals, cosmetics and nutraceuticals with 3 GMP certifications. Earlier this year, a major positive development in Colombia’s legal outlook on exporting dried cannabis flower and producing cannabis food and beverage products has made Flora Growths’ operational buildup pay off. Flora has now developed an international distribution pipeline for its GACP-certified flower produced at its Colombian facilities – where GACP is the precursor certification for the flower to be used to produce EU-GMP certified derivatives – that can be marketed to end users around the world. Flora also completed an investment program in European Union GMP partner Hoshi International Inc. in August that is expected to create a pathway for European distribution of Flora’s medical cannabis products (https://ibn.fm/xVfBa). Flora Growth President and CEO Luis Merchan will provide an update in a Dec. 14 webinar on the company’s performance for 2021 and comment on the company’s financial guidance for 2022 (https://ibn.fm/7GmNj). For more information, visit the company’s website at www.FloraGrowth.ca. NOTE TO INVESTORS: The latest news and updates relating to FLGC are available in the company’s newsroom at https://ibn.fm/FLGC

• Tryp just announced FDA confirmation for its IND application filed in November 2021
• The confirmation allows the company to proceed with its Phase 2a study on the effectiveness of psilocybin-assisted therapy among patients with fibromyalgia
• This clinical study will be one of the first to evaluate synthetic psilocybin for fibromyalgia in a Phase 2 study
• It is set to commence in 2022 and will involve 20 fibromyalgia patients

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) just announced that it would be proceeding with its upcoming Phase 2a fibromyalgia study, following a confirmation from the U.S. Food and Drug Administration (“FDA”) (https://ibn.fm/C20cT). Tryp submitted an Investigational New Drug (“IND”) application in November 2021 for its lead drug candidate, TRP-8802, to investigate the safety and preliminary effectiveness of psilocybin-assisted therapy among patients living with fibromyalgia (https://ibn.fm/dVKmq). The Phase 2a study, conducted in collaboration with Kevin Boehnke, Ph.D. from the University of Michigan, is set to kick off in 2022. This study will enroll 20 fibromyalgia patients and include a variety of secondary and exploratory endpoints, considering the high prevalence of co-morbidities such as poor sleep quality, anxiety, depression, and other conditions that patients living with fibromyalgia deal with every day. “The upcoming Phase 2a study with the University of Michigan for fibromyalgia represents a significant milestone for Tryp’s clinical programs. We are eager to begin enrolling patients in the study next year considering the significant, unmet needs of fibromyalgia patients,” noted Greg McKee, the Chairman and Chief Executive Officer (“CEO”) of Tryp Therapeutics. This clinical study will be among the first evaluations of synthetic psilocybin for fibromyalgia in a Phase 2 study. It is projected that the administration of psilocybin will increase neuroplasticity and address disrupted neural connections associated with nociplastic pain indications. Most importantly, this study will work towards shaking up the clinical thinking on how to deal with such neurological conditions while laying down the foundation for Tryp’s further studies using their novel, trademarked drug candidates. For more information, visit the company’s website at www.TrypTherapeutics.com. NOTE TO INVESTORS: The latest news and updates relating to TRYPF are available in the company’s newsroom at https://ibn.fm/TRYPF

• Company receives grant to fund clinic for marginalized, underserved NYC communities
• New clinic will offer psychedelic treatment with no out-of-pocket cost for individuals unable to afford the service
• Program’s clinicians will receive specialized training

Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing psychedelics to therapeutics, is marking key milestones in its mission to revolutionize mental healthcare. The company recently received a grant for the first-ever psychedelic treatment clinic at Lenox Hill Hospital (https://ibn.fm/zyerA). Part of Northwell Health, the largest healthcare system in New York State, Lenox Hill Hospital serves marginalized and underserved communities on the Upper East Side of Manhattan, New York. The hospital is working to become one of the first hospital-based clinical sites to offer psychedelic medicine in the United States. “It’s time for psychedelic medicine to climb down from the ivory tower and into the community,” said Cybin chief clinical officer Dr. Alex Belser. “We are honored to support this program at Lenox Hill Hospital to start a low-cost/no-cost psychedelic clinic for marginalized and underserved communities in New York.” One of Northwell Health’s flagship hospitals, Lenox Hill Hospital is a 450-bed, acute-care facility on Manhattan’s Upper East Side. The clinical program at the hospital’s Outpatient Center for Mental Health is dedicated to addressing health inequities by prioritizing care for marginalized and underserved populations. The new psychedelic treatment clinic, funded and supported in part by Cybin, will offer treatment with no out-of-pocket cost for individuals who would otherwise be unable to afford the service; the clinic will also offer psychedelic treatments to frontline healthcare workers who are having difficulty dealing with COVID-19. In addition, the program’s clinicians will receive specialized training in MDMA-, ketamine- and tryptamine-assisted psychotherapy, as well as in EMBARK, a transdiagnostic psychedelic psychotherapy model. Created by Belser and his colleague Bill Brennan, EMBARK offers a wide range of flexibility. The model can be adapted to address a range of clinical indications and populations. “Lenox Hill Hospital is excited by the potential of these modalities for the treatment of previously intractable conditions such as severe depression, chronic PTSD and OCD,” said David Roane, MD, chair of psychiatry at Lenox Hill Hospital. “With this grant from Cybin, Lenox Hill Hospital aims to become one of the first hospital-based clinical sites offering psychedelic medicine in the country and is dedicated to addressing health inequities by prioritizing care for marginalized and underserved populations. In particular, people of color are greatly underrepresented in psychedelic research studies, and our team is committed to inclusive recruitment of patients.” Cybin is a leading ethical biopharmaceutical company and is working with a network of world-class partners and internationally recognized scientists to create safe and effective therapeutics to address a multitude of mental health issues. The company operates in the United States, the United Kingdom and Ireland. The company is focused on progressing psychedelics to therapeutics by engineering proprietary drug-discovery platforms, innovative drug-delivery systems, novel formulation approaches and treatment regimens for mental-health disorders. For more information, visit the company’s website at www.Cybin.com. NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN